First-Time Generic Approvals: Cipro IV, Surmontil, Lamictal

First-Time Ware Approvals: Cipro IV, Surmontil, Lamictal

Yael Waknine
September 6, 2006 — The US Food and Drug Governing body (FDA) has approved first-time product formulations for ciprofloxacin 200-mg/20-mL, 400-mg/40-mL, and 1200-mg/20-mL single-dose vials in the attention of certain infections, including photography to inhalational anthrax; trimipramine maleate 25-mg, 50-mg, and 100-mg capsules for the attention of depression; and lamotrigine 25-mg, 100-mg, 150-mg, and 200-mg tablets for the aid of seizures and bipolar status.

Product Ciprofloxacin Introduction (Cipro IV) for Inhalational Splenic fever and More

On August 28, the FDA approved 6 first-time vino formulations for ciprofloxacin 10-mg/mL introduction (brand name Cipro IV, made by Bayer AG).

The merchandise chemical will be available in 200-mg/20-mL and 400-mg/40-mL single-dose vials from Abraxis Pharmaceutical Products; Sicor Pharmaceuticals, Inc; Hospira, Inc; and Bedford Laboratories; 1200-mg/20-mL single-dose vials will also be manufactured by Bedford.

Ciprofloxacin intravenous extraction is indicated for the idiom of infections caused by susceptible microorganisms.
This is a part of article First-Time Generic Approvals: Cipro IV, Surmontil, Lamictal Taken from "Best Antibiotic: Cipro Ciprofloxacin" Information Blog